JPH0224248B2 - - Google Patents
Info
- Publication number
- JPH0224248B2 JPH0224248B2 JP18502682A JP18502682A JPH0224248B2 JP H0224248 B2 JPH0224248 B2 JP H0224248B2 JP 18502682 A JP18502682 A JP 18502682A JP 18502682 A JP18502682 A JP 18502682A JP H0224248 B2 JPH0224248 B2 JP H0224248B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- liver damage
- arethein
- formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 206010067125 Liver injury Diseases 0.000 claims description 13
- 231100000234 hepatic damage Toxicity 0.000 claims description 13
- 230000008818 liver damage Effects 0.000 claims description 13
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- NMTZPYLSXWGDPW-UHFFFAOYSA-N 3-amino-n-(2-sulfanylethyl)propanamide Chemical compound NCCC(=O)NCCS NMTZPYLSXWGDPW-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ARJGZUUFLRKLCI-UHFFFAOYSA-N benzyl n-[3-oxo-3-(2-sulfanylethylamino)propyl]carbamate Chemical compound SCCNC(=O)CCNC(=O)OCC1=CC=CC=C1 ARJGZUUFLRKLCI-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DDDVINJUMQBWAD-UHFFFAOYSA-N s-[2-(3-acetamidopropanoylamino)ethyl] ethanethioate Chemical compound CC(=O)NCCC(=O)NCCSC(C)=O DDDVINJUMQBWAD-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57185026A JPS5973515A (ja) | 1982-10-20 | 1982-10-20 | 肝障害抑制剤 |
| US06/488,100 US4552765A (en) | 1982-05-14 | 1983-04-25 | Aletheine derivatives |
| IT21040/83A IT1164218B (it) | 1982-05-14 | 1983-05-11 | Derivati della aleteina |
| GB08313145A GB2123815B (en) | 1982-05-14 | 1983-05-12 | Aletheine derivatives |
| DE3317529A DE3317529C2 (de) | 1982-05-14 | 1983-05-13 | ß-Aletheinderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| FR8308048A FR2526792B1 (fr) | 1982-05-14 | 1983-05-16 | Derives d'aletheine utiles pour le traitement des lesions hepatiques |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57185026A JPS5973515A (ja) | 1982-10-20 | 1982-10-20 | 肝障害抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5973515A JPS5973515A (ja) | 1984-04-25 |
| JPH0224248B2 true JPH0224248B2 (enExample) | 1990-05-29 |
Family
ID=16163478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57185026A Granted JPS5973515A (ja) | 1982-05-14 | 1982-10-20 | 肝障害抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5973515A (enExample) |
-
1982
- 1982-10-20 JP JP57185026A patent/JPS5973515A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5973515A (ja) | 1984-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2261099C (fr) | Composition pharmaceutique antithrombotique et antiatherogene comprenant un derive de thienopyridine et un inhibiteur de la hmg-coa-reductase | |
| CN111635315B (zh) | 一种解热镇痛药物及其制备方法和用途 | |
| CA2674550A1 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| EP0051409B1 (en) | 2-(substituted-phenyl)-thiazole derivatives suitable for peptic ulcer treatment | |
| GB2183476A (en) | Antihypertensives | |
| CA1307739C (en) | Anti-inflammatory compositions | |
| JPH0224248B2 (enExample) | ||
| JPS615017A (ja) | 抗潰瘍組成物 | |
| Orosco et al. | Fenfluramine and brain transmitters in the obese Zucker rat | |
| JPS61155327A (ja) | ジヒドロピリジン化合物を含有する抗動脈硬化剤 | |
| US3462534A (en) | Production of an antidepressant effect with esters of gallic acid | |
| JPH03118334A (ja) | 肝障害抑制剤 | |
| JPS6313964B2 (enExample) | ||
| EP0254068B1 (en) | Novel therapeutic agent for gastritis | |
| CA2709119C (en) | Preventive or therapeutic agent for inflammatory bowel diseases | |
| AU3681899A (en) | Cyclooxygenase inhibitor | |
| JP3090211B2 (ja) | 第４級ｎ−ベンジル−ｎ−｛２−〔２−（（１ｓ，５ｓ）−６，６−ジメチルビシクロ〔３．１．１〕−ヘプト−２−イル）エトキシ〕エチル｝モルホリニウム塩を含有する胃保護作用を有する製薬学的調剤およびその製造法 | |
| JPS58164507A (ja) | ジベンゾシクロヘプテニリデン類による免疫変化剤 | |
| JPS6312843B2 (enExample) | ||
| JPH0343249B2 (enExample) | ||
| JPS60208914A (ja) | 肝障害の予防、治療剤 | |
| JPS6245525A (ja) | 脂質低下剤 | |
| JPS643168B2 (enExample) | ||
| US4555510A (en) | Therapeutic agent for hypertension | |
| JPS6241207B2 (enExample) |